Skip to main content
Clinical Trials/NCT02946723
NCT02946723
Unknown
Phase 1

A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB)With X-Ray Guided Technique

Beijing Pins Medical Co., Ltd0 sites30 target enrollmentFebruary 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Refractory Overactive Bladder
Sponsor
Beijing Pins Medical Co., Ltd
Enrollment
30
Primary Endpoint
Successful rate
Last Updated
9 years ago

Overview

Brief Summary

Overactive bladder(OAB,Urgency) was determined by International Continence Society as Urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.The SNM treatment involves a two-stage surgical procedure performed under local anesthesia. The device include IPG (implantable programme generator) and lead. In the initial test phase, 1st stage, electrode is placed near the sacral nerve and requires a 2 weeks assessment. This allows your doctors and you to assess your initial response according to your voiding dairy and satisfaction. In 2nd stage, SNM procedure is implantation of the IPG.

X ray guidance is harmful to both patients and doctors, while ultrasound guidance is real time visual guidance ,easy to operate by doctors and a radiation free option to challenge anatomy. Urologists are skilled in both ultrasound operations and anatomy basics and dedicating to developing better guidance technique in surgery.

The study here compare the efficacy and safety of ultrasound versus X ray guidance technique in SNM.

Registry
clinicaltrials.gov
Start Date
February 2017
End Date
February 2019
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age \> 16 years;
  • Subjects suitable for SNM surgery;
  • Normal upper urinary tract function;
  • Bladder volume \> 100 mL;
  • Good compliance and able to complete the follow-up assessments.

Exclusion Criteria

  • Psychiatric or neurologic disabilities on neurologic evaluation such as multiple sclerosis, spinal cord injury, epilepsy, Parkinson's disease, stroke;
  • Bladder lithiasis or tumor (cystoscopy or ultrasonography);
  • Stress urinary incontinence;
  • Bladder outlet obstruction;
  • Diuresis \> 3 liters per 24 hours;
  • Negative at the test period or previous treatment with SNM;
  • Pregnancy and plan to be pregnancy in 2 years.

Outcomes

Primary Outcomes

Successful rate

Time Frame: 6 months post -IPG implantation

Successful rate is the percentage of patients who experienced a successful result (≥50% improvements in baseline symptoms ) as recorded in voiding dairies.

Secondary Outcomes

  • Adverse effect(During operation, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation)
  • Guidance technique performance time(From beginning operation until successful lead placement is completed)
  • Overactive bladder symptom score (OABSS)(pre-operation baseline, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation)
  • Quality of Life (QoL) scores(pre-operation baseline, 2 weeks post-lead implantation, 3 and 6 months post -IPG implantation)
  • Times of X-ray radiation(During operation)

Similar Trials